Abstract
Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Current Pharmaceutical Design
Title: Antibacterial Peptides and Gastrointestinal Diseases
Volume: 17 Issue: 16
Author(s): Clover C. M. Wong, Lin Zhang, Shun X. Ren, Jing Shen, Ruby L. Y. Chan and Chi H. Cho
Affiliation:
Keywords: Defensins, Cathelicidins, Gastritis, Gastric cancer, Inflammatory bowel diseases, neutrophils, peptides, tumorigenesis, metaplasia, magainins, ceropins, in situ, hybridization, hBD-2, hBD-3, hyperexpression, peptidoglycan
Abstract: Defensins and cathelicidins are small cationic peptides produced by neutrophils and epithelial cells. They are highly expressed during infection. The role of constitutive and inducible antibacterial peptides has been extensively studied over the recent years; especially in the gastrointestinal (GI) tract, where the balance between the luminal bacteria and antibacterial peptides is crucial in the maintenance of a healthy GI tract. There are reports showing that the expressions of defensins and cathelicidins in the gut are dysregulated in various disease states. They could participate in the development of different disorders ranging from inflammation to cancer. Experimental findings showed that supplementation with animal cathelicidin promoted gastric ulcer healing in rats and suppressed tumorigenesis of gastric cancer in mice. Mouse cathelicidin could alleviate murine colitis by preserving mucus content and suppression of apoptosis. Other clinical applications for these antibacterial peptides are awaiting for further studies.
Export Options
About this article
Cite this article as:
C. M. Wong Clover, Zhang Lin, X. Ren Shun, Shen Jing, L. Y. Chan Ruby and H. Cho Chi, Antibacterial Peptides and Gastrointestinal Diseases, Current Pharmaceutical Design 2011; 17 (16) . https://dx.doi.org/10.2174/138161211796197025
DOI https://dx.doi.org/10.2174/138161211796197025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lipid Based Nanosystems for Curcumin: Past, Present and Future
Current Pharmaceutical Design Helicobacter Pylori Infection, Immune Response and Vaccination
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Microemulsions: A Novel Approach to Enhanced Drug Delivery
Recent Patents on Drug Delivery & Formulation Gastric Cancer: Nanoparticles as Tools to Improve Treatment Efficacy
Current Pharmaceutical Design Oral L-Carnitine: Metabolite Formation and Hemodialysis
Current Drug Metabolism Targeting Endothelial Progenitor Cells in Cancer as a Novel Biomarker and Anti-Angiogenic Therapy
Current Stem Cell Research & Therapy Beneficial Actions of Polyunsaturated Fatty Acids in Cardiovascular Diseases: But, How and Why?
Current Nutrition & Food Science Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy
Clinical Cancer Drugs Targeting Intestinal Transporters for Optimizing Oral Drug Absorption
Current Drug Metabolism Multifunctionalized Microbubbles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry Chalcones Incorporated Pyrazole Ring Inhibit Proliferation, Cell Cycle Progression, Angiogenesis and Induce Apoptosis of MCF7 Cell Line
Anti-Cancer Agents in Medicinal Chemistry Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Challenges and Perspectives in the Discovery of Dengue Virus Entry Inhibitors
Current Medicinal Chemistry Targeted Tumor Immunotherapy: Are Vaccines the Future of Cancer Treatment?
Current Drug Therapy Modulation of Potassium Channels as a Therapeutic Approach
Current Pharmaceutical Design The Roles of Antimicrobial Peptides in Innate Host Defense
Current Pharmaceutical Design Chlorella vulgaris Induces Apoptosis of Human Non-Small Cell Lung Carcinoma (NSCLC) Cells
Medicinal Chemistry Metabolic Profiling in Disease Diagnosis, Toxicology and Personalized Healthcare
Current Pharmaceutical Biotechnology RNA Interference: A New Targeted Tumour Therapy?
Current Cancer Therapy Reviews Current Immune Therapies of Autoimmune Disease of the Nervous System with Special Emphasis to Multiple Sclerosis
Current Pharmaceutical Design